 SAN DIEGO, July 23, 2021 GLOBE NEWSWIRE -- Sorrento Therapeutics, Inc. Nasdaq: SRNE, Sorrento and Lees Pharmaceutical Holdings Limited HKEX: 950, Lees Pharm announced today that, on July 15, 2021, China Oncology Focus Limited COF, a subsidiary of Lees Pharm, has enrolled the first patient in China in the Phase 3, multicenter, randomized, double blinded, placebo controlled clinical trial of Socazolimab anti-PD-L1 monoclonal antibody, formerly known as ZKAB001 combined with chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer ES-SCLC. The clinical trial clearance was granted by Chinas National Medical Products Administration NMPA in March 2021. 